Acetazolamide
- Generic Name
- Acetazolamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C4H6N4O3S2
- CAS Number
- 59-66-5
- Unique Ingredient Identifier
- O3FX965V0I
- Background
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of...
- Indication
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
- Associated Conditions
- Acute angle-closure glaucoma, Edema, Familial periodic paralysis, Generalized Tonic-Clonic Seizures, Metabolic Alkalosis, Open Angle Glaucoma (OAG), Other and unspecified effects of high altitude, Cystine renal calculi, Drug-induced edema, Nonuveitic secondary glaucoma, Salicylate intoxication
- Associated Therapies
- Urine alkalinization therapy
Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06091085
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Managing Opioid Related Sleep Apnea With Acetazolamide
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 34
- Registration Number
- NCT06043830
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stadtspital Zürich
- Target Recruit Count
- 75
- Registration Number
- NCT05986773
- Locations
- 🇨🇭
Stadtspital Zürich, Zürich, Switzerland
Acetazolamide Per os for Decompensation of Heart Failure
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Samara State Medical University
- Target Recruit Count
- 400
- Registration Number
- NCT05802849
- Locations
- 🇷🇺
Samara state medical university, Samara, Russian Federation
Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 60
- Registration Number
- NCT05804084
- Locations
- 🇺🇸
UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 46
- Registration Number
- NCT05616260
- Locations
- 🇺🇸
UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
Acetazolamide on REM OSA
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05589792
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sleep Disordered Breathing With Opioid Use
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 150
- Registration Number
- NCT05589753
- Locations
- 🇺🇸
John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States
Acetazolamide in Persons With Type 1 Diabetes
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 12
- Registration Number
- NCT05473364
- Locations
- 🇺🇸
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05470283
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.